| References |
| 1 |
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients Drug Metab Dispos. 2000 Apr;28(4):423-33.
|
| 2 |
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):317-324. doi: 10.1007/s13318-021-00675-3.
|
| 3 |
Structural insights into catalytical capability for CPT11 hydrolysis and substrate specificity of a novel marine microbial carboxylesterase, E93. Front Microbiol. 2023 Jan 11;13:1081094. doi: 10.3389/fmicb.2022.1081094.
|
| 4 |
Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Cancer Chemother Pharmacol. 2021 Aug;88(2):247-258. doi: 10.1007/s00280-021-04255-9.
|
| 5 |
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
|
| 6 |
The gut microbiome: an orchestrator of xenobiotic metabolism
|
| 7 |
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
|
| 8 |
Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors
|
